<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Altamira Therapeutics</title>
    <link>https://www.biospace.com/employer/3076397/altamira-therapeutics</link>
    <description>Altamira Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Fri, 06 Aug 2021 13:06:08 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076397/altamira-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)</title>
      <link>https://www.biospace.com/altamira-therapeutics-reports-protective-effects-of-bentrio-tm-nasal-spray-against-influenza-a-virus-h1n1</link>
      <description>Altamira Therapeutics Ltd. today announced positive outcomes from testing Bentrio™ for prophylactic or therapeutic use in influenza A virus infection.</description>
      <pubDate>Fri, 06 Aug 2021 13:06:08 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-reports-protective-effects-of-bentrio-tm-nasal-spray-against-influenza-a-virus-h1n1</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results</title>
      <link>https://www.biospace.com/altamira-therapeutics-provides-business-update-and-reports-first-half-2021-financial-results</link>
      <description>Altamira Therapeutics Ltd. today provided a business update and announced first half 2021 financial results.</description>
      <pubDate>Wed, 08 Sep 2021 12:36:15 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-provides-business-update-and-reports-first-half-2021-financial-results</guid>
    </item>
    <item>
      <title>Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference</title>
      <link>https://www.biospace.com/altamira-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference</link>
      <description>Altamira Therapeutics Ltd. today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, to be held virtually September 13-15, 2021.</description>
      <pubDate>Thu, 09 Sep 2021 12:36:16 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference</guid>
    </item>
    <item>
      <title>Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program</title>
      <link>https://www.biospace.com/altamira-therapeutics-to-provide-business-update-on-bentrio-tm-program</link>
      <description>Altamira Therapeutics Ltd. announced that it will provide a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens, through a live conference call and webcast on Monday, September 27, 2021, at 8:00 AM Eastern Time.</description>
      <pubDate>Tue, 21 Sep 2021 12:06:18 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-to-provide-business-update-on-bentrio-tm-program</guid>
    </item>
    <item>
      <title>Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference</title>
      <link>https://www.biospace.com/altamira-therapeutics-to-participate-in-a-g-p-s-virtual-biotech-and-specialty-pharma-conference</link>
      <description>Altamira Therapeutics Ltd. today announced that management will participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference on October 13, 2021.</description>
      <pubDate>Wed, 06 Oct 2021 12:06:19 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-to-participate-in-a-g-p-s-virtual-biotech-and-specialty-pharma-conference</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application</title>
      <link>https://www.biospace.com/altamira-therapeutics-receives-fda-acceptance-for-bentrio-510-k-application</link>
      <description>Altamira Therapeutics Ltd. today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration for its Bentrio nasal spray for protection against airborne allergens has cleared the Agency's acceptance review.</description>
      <pubDate>Thu, 14 Oct 2021 12:06:14 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-receives-fda-acceptance-for-bentrio-510-k-application</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant</title>
      <link>https://www.biospace.com/altamira-therapeutics-reports-positive-in-vitro-efficacy-data-for-bentrio-nasal-spray-in-protecting-against-sars-cov-2-delta-variant</link>
      <description>Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.</description>
      <pubDate>Fri, 12 Nov 2021 14:06:12 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-reports-positive-in-vitro-efficacy-data-for-bentrio-nasal-spray-in-protecting-against-sars-cov-2-delta-variant</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021</title>
      <link>https://www.biospace.com/altamira-therapeutics-announces-poster-presentations-at-aha-scientific-sessions-2021</link>
      <description>Altamira Therapeutics Ltd. announced the presentation of data from two studies by a research group at Washington University, St. Louis, MO, on the use of the Company's RNA delivery platforms for extrahepatic nucleotide delivery in the treatment of abdominal aortic aneurysm at the American Heart Association Scientific Sessions, taking place on November 13-15, 2021.</description>
      <pubDate>Mon, 15 Nov 2021 14:06:09 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-announces-poster-presentations-at-aha-scientific-sessions-2021</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis</title>
      <link>https://www.biospace.com/altamira-therapeutics-announces-randomization-of-first-patient-in-bentrio-trial-in-seasonal-allergic-rhinitis</link>
      <description>Altamira Therapeutics Ltd. today announced that the first patient has been randomized in its trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis.</description>
      <pubDate>Wed, 01 Dec 2021 14:06:11 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-announces-randomization-of-first-patient-in-bentrio-trial-in-seasonal-allergic-rhinitis</guid>
    </item>
    <item>
      <title>Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy</title>
      <link>https://www.biospace.com/altamira-therapeutics-announces-randomization-of-first-patients-in-bentrio-trial-in-house-dust-mite-allergy</link>
      <description>Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced that the first group of patients has been randomized in a clinical trial with Bentrio™ in house dust mite allergic rhinitis.</description>
      <pubDate>Thu, 16 Dec 2021 14:06:11 GMT</pubDate>
      <guid>https://www.biospace.com/altamira-therapeutics-announces-randomization-of-first-patients-in-bentrio-trial-in-house-dust-mite-allergy</guid>
    </item>
  </channel>
</rss>
